Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.39 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.38 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.38 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 6/20 | 0.38 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.37 |
| ▸ | MGLL | Q99685 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.34 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3421930 | 1.00 | KMT2A (0.49) | KMT2AZDHHC2PRSS1PRSS2PRSS3 | |
| SCHEMBL2854760 | 0.84 | KMT2A (0.55) | KMT2AP2RX3 | |
| SCHEMBL2854762 | 0.84 | KMT2A (0.55) | KMT2AP2RX3 | |
| SCHEMBL3968978 | 0.77 | KMT2A (0.54) | KMT2A | |
| SCHEMBL7214893 | 0.76 | KMT2A (0.60) | KMT2APRSS1FAAHLTA4H | |
| SCHEMBL10656076 | 0.76 | KMT2A (0.59) | KMT2A | |
| SCHEMBL10656070 | 0.76 | KMT2A (0.59) | KMT2A | |
| SCHEMBL11290548 | 0.75 | ACHE (0.42) | KMT2A | |
| SCHEMBL11290545 | 0.75 | ACHE (0.42) | KMT2A | |
| SCHEMBL9865297 | 0.73 | KMT2A (0.38) | KMT2AP2RX3SCN5ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791830-B1 | DIAMINOTRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7329652-B2 | Diaminotriazole compounds useful as protein kinase inhibitors | VERTEX PHARAMACEUTICALS INCORPORATED (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1791830-A1 | DIAMINOTRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006034116-A1 | DIAMINOTRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063756-A1 | Diaminotriazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063756-A1 | Diaminotriazole compounds useful as protein kinase inhibitors | JAK2, JAK3, JAK1 | KMT2A 726/4885ZDHHC2 2547/4885PRSS1 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.